Supreme Court weighs the fate of telehealth access to the abortion pill

The U.S. Supreme Court granted a one-week stay on May 4, 2026, blocking a federal appeals court ruling that would have ended nationwide telemedicine access to mifepristone, an abortion pill. The ruling, issued on May 1, had caused uncertainty over whether patients could still receive the drug via mail or telehealth, but the stay allows prescriptions to continue through May 11. The appeals court decision, upheld by Louisiana’s lawsuit against the FDA, challenged the agency’s 2023 rule expanding telehealth access for mifepristone. Louisiana argued that remote prescriptions undermined its strict abortion ban, while the FDA—represented by the Department of Justice—did not file a brief defending the rule by the May 7 deadline. Legal experts noted the DOJ’s inaction as unusual, given the FDA’s role as the defendant in the case. Telemedicine abortion has grown significantly since the Supreme Court overturned *Roe v. Wade* in 2022, now accounting for one-quarter of U.S. abortions. The Guttmacher Institute estimated 1.1 million abortions in 2025, partly due to expanded telehealth access. Louisiana has led anti-abortion legal challenges, becoming the first state to classify mifepristone as a controlled substance and indict out-of-state physicians for telemedicine abortions. The Supreme Court’s next steps remain unclear, with Justice Samuel Alito potentially extending the stay or allowing it to expire, which could reinstate restrictions while the case proceeds. The legal battle hinges on the FDA’s authority to regulate prescription drugs and the broader implications for abortion access nationwide. Louisiana’s lawsuit targets the FDA’s 2023 policy, which relaxed in-person requirements for mifepristone during the COVID-19 pandemic. The state’s argument centers on enforcing its abortion ban amid rising telehealth usage, raising questions about federal vs. state regulatory power. The case continues to unfold amid ongoing debates over reproductive rights and healthcare access.